I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

A number of stocks jumped in the afternoon session after markets continued to rally as investor optimism grew for a potential ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

We are not close. After my father passed, she kicked us to the curb - not only financially but also emotionally and as a parent. Even though I was 20 when he died, I grew up in a family where we were ...

Upstart's growth following its 2023/2024 slowdown looks like it’s going to stick this time around. Yes, MercadoLibre missed last quarter's earnings expectations. Now take a step back and look at the ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...